% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{WangDietrich:133640,
      author       = {Wang-Dietrich, Lei and Funke, Aileen and Kühbach, Katja
                      and Wang, Kun and Besmehn, Astrid and Willbold, Sabine and
                      Cinar, Yeliz and Bannach, Oliver and Birkmann, Eva and
                      Willbold, Dieter},
      title        = {{T}he {A}myloid-β {O}ligomer {C}ount in {C}erebrospinal
                      {F}luid is a {B}iomarker for {A}lzheimer's {D}isease},
      journal      = {Journal of Alzheimer's disease},
      volume       = {34},
      number       = {4},
      issn         = {1387-2877},
      address      = {Amsterdam},
      publisher    = {IOS Press},
      reportid     = {FZJ-2013-02055},
      pages        = {985-994},
      year         = {2013},
      abstract     = {Recent studies indicate that small amyloid-β peptide (Aβ)
                      oligomers are the major toxic species responsible for
                      development and progression of Alzheimer's disease (AD).
                      Therefore, we suggest that the number of Aβ oligomers in
                      body fluids is the most direct and relevant biomarker for
                      AD. Determination of the Aβ oligomer content of
                      cerebrospinal fluid (CSF) samples from 14 AD patients and 12
                      age-matched controls revealed a clear distinction between
                      both groups. All samples of the control group showed
                      homogenously low numbers of Aβ oligomers, while the samples
                      of the AD group exhibited significantly higher levels of Aβ
                      oligomers. The Aβ oligomer numbers correlated with the
                      patients' Mini-Mental State Examination scores. This
                      indicates that the quantity of Aβ oligomers in CSF reflects
                      the severity of the disease and that Aβ oligomers play a
                      crucial role in AD pathology and in turn can be used as a
                      diagnostic biomarker.},
      cin          = {ICS-6 / ZEA-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)ICS-6-20110106 / I:(DE-Juel1)ZEA-3-20090406},
      pnm          = {452 - Structural Biology (POF2-452) / 331 - Signalling
                      Pathways and Mechanisms in the Nervous System (POF2-331)},
      pid          = {G:(DE-HGF)POF2-452 / G:(DE-HGF)POF2-331},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000316464700016},
      pubmed       = {23313925},
      doi          = {10.3233/JAD-122047},
      url          = {https://juser.fz-juelich.de/record/133640},
}